Member Posts > Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL): Myocarditis Treatment Evolution - How CardiolRx™ is Redefining Care
🚀 ARCHER Phase II Trial is testing CardiolRx™ as a potential first-in-class myocarditis therapy.
🚀 Targets inflammation, heart scarring, and long-term dysfunction.
🚀 Results expected in 2025, paving the way for regulatory approval.
🔗 Follow the progress of this groundbreaking treatment:

#HealthcareRevolution #BiotechInnovation